Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CRHBP | P24387 | 2/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23774829 | 1.00 | MEN1 (0.60) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL21466931 | 1.00 | MEN1 (0.60) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL4681925 | 0.81 | MEN1 (0.86) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL14853295 | 0.81 | MEN1 (0.64) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL4151615 | 0.79 | MME (0.63) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL4594451 | 0.79 | MEN1 (0.62) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL18456226 | 0.79 | MME (0.63) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL5550287 | 0.79 | MEN1 (0.67) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL12205972 | 0.79 | MME (0.63) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL20619928 | 0.79 | ALDH1A1 (0.61) | MEN1KMT2ASMN1; SMN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230041951-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | Oncternal Therapeutics, Inc. | 2023-02-09 | — | — | US | disclosed |
| US-11273147-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210253525-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-08-19 | — | — | US | disclosed |
| US-10865184-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-15 | — | — | US | disclosed |
| US-10806720-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200222365-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | Oncternal Therapeutics, Inc. (US) | 2020-07-16 | — | — | US | disclosed |
| US-10441570-B2 | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190144387-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2019-05-16 | — | — | US | disclosed |
| US-10035763-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | GTX, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170166526-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | ONCTERNAL THERAPEUTICS, INC | 2017-06-15 | — | — | US | disclosed |
| WO-2001017992-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041951-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, BRDT | MEN1 2983/4885KMT2A 968/4885SMN1; SMN2 765/4885 |
| US-10441570-B2 | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof | AR, AHR, BRDT | MEN1 2983/4885KMT2A 968/4885SMN1; SMN2 765/4885 |
| US-11273147-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | MEN1 2983/4885KMT2A 968/4885SMN1; SMN2 765/4885 |
| US-20170166526-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, ADRM1 | MEN1 3223/4885KMT2A 1022/4885SMN1; SMN2 633/4885 |
| US-20210253525-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, BRDT | MEN1 2983/4885KMT2A 968/4885SMN1; SMN2 765/4885 |
| US-10865184-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | MEN1 2983/4885KMT2A 968/4885SMN1; SMN2 765/4885 |
| US-20200222365-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, BRDT | MEN1 2983/4885KMT2A 968/4885SMN1; SMN2 765/4885 |
| US-10806720-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, FSHR | MEN1 2865/4885KMT2A 970/4885SMN1; SMN2 173/4885 |
| US-20190144387-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, BRDT | MEN1 2983/4885KMT2A 968/4885SMN1; SMN2 765/4885 |
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | MEN1 2983/4885KMT2A 968/4885SMN1; SMN2 765/4885 |
| US-10035763-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, ADRM1 | MEN1 3223/4885KMT2A 1022/4885SMN1; SMN2 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.